八十岁母亲肺腺癌，抗癌六年

草船借箭 · 发表于 2014-7-10 10:21:33

本帖最后由草船借箭于 2014-7-10 10:23 编辑

核磁检查结论：1、双侧额顶叶散在腔隙性脑缺血、梗塞灶；2、双侧上颌窦炎症
问题分析：说明你有腔隙性脑梗塞，但位置双侧额叶，问题不是很大，老年人常见。
意见建议：建议，行对症治疗，改善脑供血，同时预防脑梗塞，脑卒中形成，控制血压，血脂，血糖等危险因素。
问题分析：腔隙性脑梗塞是脑梗塞的一种特殊类型，是在高血压、腔隙性脑梗塞* o( }4 H* j3 k/ G0 }) r; _
动脉硬化的基础上，脑深部的微小动脉发生闭塞，引起脑组织缺血性软化病变。临床上患者多无明显症状，约有3/4的患者无病灶性神经损害症状，或仅有轻微注意力不集中、记忆力下降、轻度头痛头昏、眩晕、反应迟钝等症状。该病的诊断主要为CT或MRI检查。而多发性的腔隙性脑梗塞，可影响脑功能，导致智力进行性衰退，最后导致脑血管性痴呆。
意见建议：该病的治疗，基本上同脑血栓形成，应积极治疗高血压，尤为病史中已有过腔隙性梗塞者需要防止复发，同时应注意血压不能过快过低。建议尊医嘱，规范治疗
http://club.xywy.com/static/20121211/16360007.htm

草船借箭 · 发表于 2014-7-10 15:08:49

本帖最后由草船借箭于 2014-7-10 16:00 编辑

草船借箭 2014-5-27 20:52:42
草船-母肺腺 2992(172905120) 20:51:03
GNC银杏胶囊，珈蓝空间我看到过
珈蓝，母9291中(1151227658) 20:51:05
脑梗可以吃GNC银杏胶囊，一天2-3粒。虽然只是保健药，但我身边已经有不少人脑梗吃了后大为改善的

http://www.letsebuy.com/thread-381467-1-1.html

草船借箭 · 发表于 2014-7-10 16:41:48

http://mp.weixin.qq.com/s?__biz= ... uVVSuRp1XM1Lb0bwmFf

草船借箭 · 发表于 2014-7-11 16:30:25

今天医生说肿瘤总体增长的并不太多，略微增大，且与2013.10.29的CT片子对比基本差不多。而且目前胸水总体来说控制的还可以。虽然肿瘤稍微增大、而且肿标也增长，但是总体进展还是不大。而且从身体和精神状态来看都还可以。

tdp3488286 · 发表于 2014-7-14 23:01:29

除了好运，还有作为儿子的你刻苦钻研，大胆实践，相信会越走越远！也感谢你搜集的资料为大家作出的贡献！顶！！

草船借箭 · 发表于 2014-7-15 09:34:58

7.12开始9291加服一片易瑞沙，等待我的新药到来。

zwcxkboy · 发表于 2014-7-15 09:42:01

草船兄新药准备换什么了

草船借箭 · 发表于 2014-7-15 10:04:01

本帖最后由草船借箭于 2014-7-15 10:41 编辑

http://www.18222788817.com/kangairiji/2013/24.html
易瑞沙如何减量服用？

http://blog.sina.com.cn/s/blog_66cd4ad301010vht.html
EGFR突变的晚期NSCLC患者，低剂量吉非替尼疗效不劣于常规剂量

肺腺-属-Y-易 10:09:57
易的达峰时间是3-7小时，就算平均5小时达到药峰浓度
肺腺-属-Y-易 10:10:33
消除从5小时后开始

肺腺-属-Y-易 10:26:56
有几个关于低剂量的易的临床是使用隔天一片的方案
肺腺-属-Y-易 10:27:10
NEJ002

肺腺-属-Y-易 10:29:34
你百度＂NEJ002 低剂量＂
肺腺-属-Y-易 10:29:43
第一个链接就是

肺腺-属-Y-易 10:29:58
但是没写低剂量方案

草船借箭 10:31:31
没写隔天服用还是减量每天服用
肺腺-属-Y-易 10:32:31
ASCO摘要里面写的是＂大多数患者换成每两天一次的给药方案＂
肺腺-属-Y-易 10:32:50
every-2 day schedule

肺腺-属-Y-易 10:34:40
2011年11月发表在JTO上面一片研究低剂量易对晚期患者疗效的论文

肺腺-属-Y-易 10:35:48
里面也采用了NEJ002的方案隔天一片
changing the everyday schedule to every 2 days schedule

肺腺-属-Y-易 10:40:29
临床设计看起来偏向于隔天一片

stch509 · 发表于 2014-7-15 10:55:18

草船借箭发表于 2014-7-15 09:34
% H! S1 T$ p8 B/ _% V7 _% e9 R7.12开始9291加服一片易瑞沙，等待我的新药到来。

又准备吃什么新药啊
9291效果不好吗？

costa_na · 发表于 2014-7-15 11:18:41

草船借箭发表于 2014-7-15 10:04
3 K' i$ H- m# | X" `! f. Ghttp://www.18222788817.com/kangairiji/2013/24.html
8 H8 U" p6 J+ d易瑞沙如何减量服用？

The efficacy of low-dose gefitinib for advanced non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR) mutations: A post-hoc analysis from NEJ002.

Abstract:

Background: NEJ002, a phase III trial comparing gefitinib with carboplatin-paclitaxel as the first-line treatment for advanced NSCLC with sensitive EGFR mutations, showed a significant improvement in progression-free survival (PFS) in the gefitinib arm. Although standard schedule of gefitinib was the administration of 250 mg tablet every day, more than half of patients in the gefitinib arm reduced the dose of gefitinib mainly because of toxicities. However, the efficacy of such low-dose (LD) gefitinib has rarely been evaluated.

Methods: A post-hoc analysis of the efficacy (response rate and survival) in patients who took gefitinib without any dose reduction during their treatment period and those in patients who received LD gefitinib at any point during the treatment period was performed.

Results: Among 114 patients of the first-line gefitinib group in NEJ002, 52 (46%) continued gefitinib without break until their diseases progressed (categorize as group A), and 62 (54%) was reduced their dose of gefitinib (most of them moved into every-2-days schedule) because of some toxicities (same as group B). There was no significant difference of patient characteristics between two groups. Interestingly, PFS of group B seemed to be better than that of group A (median PFS, 301 days in group A versus 351 days in group B; p = 0.450) and overall survival was also similar between the groups (median survival time, 852 days versus 928 days, respectively; p = 0.674).
62名患者减量服用吉非替尼(大多数换成了两天一片的用药方案)

Conclusions: The results suggest that LD gefitinib may be clinically not inferior to standard schedule of gefitinib for NSCLC with sensitive EGFR mutations. Considering the merit in terms of risk-benefit balance, prospective study of LD gefitinib is warranted.

http://meetinglibrary.asco.org/content/43760-74